STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens...(ing ophthalmic research firm reports tha...),Health

Date:8/20/2009

ing ophthalmic research firm, reports that the worldwide average rate of myopia is 23% of the population, while the rate in Japan is 45%. This compares to an estimated 27% prevalence rate of myopia in the U.S. The Tajimi Study which evaluated the prevalence of myopia in Japan reported that the percentage of moderate and high myopes in the pool of myopes is very high in Japan. In fact, the prevalence rate of myopia climbs to 70% for those Japanese who are in the age group of 40 to 49. Additionally, 15% of that age group suffers from high myopia which is also a much higher rate than other parts of the world. Currently over 70% of the refractive procedures in Japan are performed in a laser centers and the Visian ICL should allow more ophthalmologists to participate in this growing refractive market. Thus, a very favorable market environment should await the Visian ICL, and with our own sales and distribution organization in place in Japan, we are well positioned to meet the market's needs," added Mr. Caldwell.

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 50 countries. Collamer(R) is the brand name for STAAR's proprietary collagen copolymer lens material. More information is available at www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: prospects for approval t
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. STAAR Surgical Generates Cash From Operations During Second Quarter
2. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
5. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
6. Richard A. Meier Appointed to STAAR Surgical Board of Directors
7. STAAR Surgical Completes Common Stock Offering
8. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
9. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
10. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
11. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses